Figure 1
Expression of TXS and its metabolite TXB 2 in tumour and matched control patient samples. A) Expression of TXS in a retrospective panel of tumour/normal matched protein samples. Over-expression of TXS protein was observed in adenocarcinoma and squamous cell carcinoma samples, relative to matched normal (n = 13/group). B) All blots were stripped and re-probed for β-actin to normalise for loading differences (N = normal, T = matched tumour). C) Thromboxane metabolite generation in NSCLC plasma samples and age-matched controls. Plasma levels of the thromboxane metabolite, thromboxane B2, were significantly higher in plasma from NSCLC patients than in age-matched controls (C; * p < 0.01; n = 49 patient, 19 controls).